Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT00935311
First received: June 29, 2009
Last updated: March 10, 2014
Last verified: March 2014
History of Changes
Results First Received: November 1, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Pain
Interventions: Drug: ABT-712 Extended-release
Drug: Hydrocodone/Acetaminophen Immediate-release
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ABT-712 1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Hydrocodone/Acetaminophen 2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
Placebo 2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).

Participant Flow:   Overall Study
    ABT-712     Hydrocodone/Acetaminophen     Placebo  
STARTED     43     39     40  
COMPLETED     43     39     40  
NOT COMPLETED     0     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ABT-712 1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Hydrocodone/Acetaminophen 2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
Placebo 2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Total Total of all reporting groups

Baseline Measures
    ABT-712     Hydrocodone/Acetaminophen     Placebo     Total  
Number of Participants  
[units: participants]
 		  43     39     40     122  
Age  
[units: years]
Mean (Standard Deviation) 		  22.1  (2.83)     21.4  (3.20)     23.0  (4.73)     22.2  (3.70)  
Gender  
[units: participants]
 		       
Female     22     23     28     73  
Male     21     16     12     49  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS)   [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]
  Show Outcome Measure 1

2.  Secondary:   TOTPAR (Total Pain Relief)   [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]
  Show Outcome Measure 2

3.  Secondary:   Time to First Rescue Medication   [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]
  Show Outcome Measure 3

4.  Secondary:   Participants With Adverse Events (AEs)   [ Time Frame: AEs were recorded from study drug administration until 30 days following discontinuation of study drug (total 30 days); SAEs were recorded from the time informed consent was obtained until 30 days following discontinuation of study drug (total 51 days). ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: AbbVie (prior sponsor, Abbott)
phone: 800-633-9110



Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT00935311     History of Changes
Other Study ID Numbers: M11-063
Study First Received: June 29, 2009
Results First Received: November 1, 2013
Last Updated: March 10, 2014
Health Authority: United States: Food and Drug Administration